Kissei Pharmaceutical Co., Ltd.

Kissei Pharmaceutical Co., Ltd. logo
🇯🇵Japan
Ownership
Public
Established
1946-08-09
Employees
1.7K
Market Cap
-
Website
http://www.kissei.co.jp

A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

First Posted Date
2013-10-25
Last Posted Date
2018-12-14
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
374
Registration Number
NCT01970098

A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-09-10
Last Posted Date
2014-11-13
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Registration Number
NCT01938196

A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-09-09
Last Posted Date
2014-11-13
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Registration Number
NCT01937663

A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

First Posted Date
2013-07-02
Last Posted Date
2015-10-19
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Registration Number
NCT01890941

A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2013-05-14
Last Posted Date
2014-11-13
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Registration Number
NCT01852682

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

First Posted Date
2013-05-09
Last Posted Date
2018-10-09
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
213
Registration Number
NCT01850602

A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2013-05-09
Last Posted Date
2018-10-09
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
35
Registration Number
NCT01850641

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2013-04-17
Last Posted Date
2018-10-09
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
161
Registration Number
NCT01833494
Locations
🇯🇵

JAPAN, Multiple Locations, Japan

A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-09-25
Last Posted Date
2014-05-30
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Registration Number
NCT01692145
Locations
🇯🇵

Japan, Tokyo and Other Japanese City, Japan

A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-06-27
Last Posted Date
2014-05-30
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
20
Registration Number
NCT01629420
Locations
🇯🇵

Japan, Tokyo and Other Japanese City, Japan

© Copyright 2024. All Rights Reserved by MedPath